JP2009539877A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539877A5
JP2009539877A5 JP2009514546A JP2009514546A JP2009539877A5 JP 2009539877 A5 JP2009539877 A5 JP 2009539877A5 JP 2009514546 A JP2009514546 A JP 2009514546A JP 2009514546 A JP2009514546 A JP 2009514546A JP 2009539877 A5 JP2009539877 A5 JP 2009539877A5
Authority
JP
Japan
Prior art keywords
diabetes
group
phenylacetic acid
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009514546A
Other languages
English (en)
Japanese (ja)
Other versions
JP5252585B2 (ja
JP2009539877A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/070691 external-priority patent/WO2007146768A2/en
Publication of JP2009539877A publication Critical patent/JP2009539877A/ja
Publication of JP2009539877A5 publication Critical patent/JP2009539877A5/ja
Application granted granted Critical
Publication of JP5252585B2 publication Critical patent/JP5252585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009514546A 2006-06-09 2007-06-08 代謝障害の治療のための化合物 Expired - Fee Related JP5252585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80433606P 2006-06-09 2006-06-09
US60/804,336 2006-06-09
PCT/US2007/070691 WO2007146768A2 (en) 2006-06-09 2007-06-08 Compounds for the treatment of metabolic disorders

Publications (3)

Publication Number Publication Date
JP2009539877A JP2009539877A (ja) 2009-11-19
JP2009539877A5 true JP2009539877A5 (enExample) 2011-07-21
JP5252585B2 JP5252585B2 (ja) 2013-07-31

Family

ID=38832700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009514546A Expired - Fee Related JP5252585B2 (ja) 2006-06-09 2007-06-08 代謝障害の治療のための化合物

Country Status (12)

Country Link
US (1) US20100234464A1 (enExample)
EP (1) EP2026659A4 (enExample)
JP (1) JP5252585B2 (enExample)
KR (1) KR101391905B1 (enExample)
CN (1) CN101466266A (enExample)
AU (1) AU2007257854B2 (enExample)
CA (1) CA2654530A1 (enExample)
IL (1) IL195392A0 (enExample)
MX (1) MX2008015640A (enExample)
NZ (1) NZ573031A (enExample)
WO (1) WO2007146768A2 (enExample)
ZA (1) ZA200809774B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2240024A4 (en) * 2008-01-15 2014-05-21 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
MX2010009959A (es) 2008-03-13 2010-10-04 Wellstat Therapeutics Corp Compuestos y metodo para reducir el acido urico.
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
CN119403529A (zh) 2022-07-01 2025-02-07 国立大学法人东京大学 体表面溃疡治愈促进装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354602B1 (en) * 2000-12-26 2006-10-04 Sankyo Company, Limited Medicinal compositions containing diuretic and insulin resistance-improving agent
KR100965201B1 (ko) * 2001-06-12 2010-06-24 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
US7645772B2 (en) * 2002-11-01 2010-01-12 Wellstat Therapeutics Corporation Treatment of metabolic disorders
EP1601251B1 (en) * 2003-02-13 2014-11-12 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
DK1633340T3 (da) * 2003-04-15 2011-02-07 Wellstat Therapeutics Corp Forbindelser til behandling af stofskifteforstyrrelser
CN1777576A (zh) * 2003-04-22 2006-05-24 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
US7442796B2 (en) * 2003-04-30 2008-10-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2533890A1 (en) * 2003-08-20 2005-03-03 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007087505A2 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
AU2007208127A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Similar Documents

Publication Publication Date Title
JP2009537559A5 (enExample)
KR101860120B1 (ko) 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
JPH01503539A (ja) 非鎮静抗ヒスタミン薬を含んでなる咳／風邪用混合物
TW201136916A (en) New uses
JP2009528275A5 (enExample)
TW200406204A (en) Combination of organic compounds
RU2005128501A (ru) Соединение для лечения метаболических расстройств
TW200305415A (en) Combination of organic compounds
CN101410105A (zh) 代谢紊乱的组合治疗
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
JP2006514100A (ja) 徐放性ｌ−アルギニン製剤並びに製造方法および使用方法
JP2006524252A5 (enExample)
CA2502297A1 (en) Compounds for the treatment of metabolic disorders
JP5490409B2 (ja) スタチンおよびメチルニコチンアミド誘導体を含んでなるリポ蛋白質異常の処置用調剤
JP2009539877A5 (enExample)
CA2521589A1 (en) Compounds for the treatment of metabolic disorders
JP2004518756A (ja) Ｇｌｐ−１類似体およびｐｐａｒリガンドの誘導体の組み合わせ使用
EP1772149A1 (en) Drug for prevention or treatment of diabetes
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
JP2009524686A5 (enExample)
CN1777417A (zh) PPARα激动剂和二甲双胍降低血清甘油三酯的用途
WO2006001092A1 (ja) インスリン分泌促進剤
US9433602B2 (en) Combination and composition for treating obesity
CN1414847A (zh) 含吡喹酮的缓释抗蠕虫组合物